Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine plus Realgar-Indigo naturalis Formula in MDS-RAEB and CMML
ChiCTR-OPN-17011153Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine and Compound Huangdai Tablet in myelodysplastic syndrome with excess blasts (MDS-EB) and chronic myelomonocytic leukemia (CMML), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: overall response rate. Planned start Apr 2017; status: not yet recruiting.
02
Drugs
decitabineCompound Huangdai Tablet
03
Conditions
myelodysplastic syndrome with excess blasts (MDS-EB)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on ChiCTR-OPN-17011153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-17011153.